Today: 20 March 2026
Bradesco stock drops on 2026 guidance — what BBDC4 investors watch next week
7 February 2026
2 mins read

Bradesco stock drops on 2026 guidance — what BBDC4 investors watch next week

Sao Paulo, February 7, 2026, 08:51 (BRT) — Market closed

  • Bradesco’s preferred shares dropped in the last session, with the bank’s 2026 targets signaling slower growth in certain areas.
  • The lender posted higher fourth-quarter profit and gave investors a fresh look at its turnaround plan.
  • Monday brings Brazil inflation numbers into focus, with traders also eyeing a new batch of bank earnings for hints on rates and credit trends.

Banco Bradesco S.A.’s preferred shares (BBDC4) slipped 2.55% on Friday, finishing at 20.61 reais. The stock moved in a range from 19.83 to 20.70 reais during the session, with roughly 94.1 million shares changing hands. Investors now have new guidance in play before trading picks up again Monday. Investing.com Brasil

The backdrop was stronger. Brazil’s Ibovespa closed Friday with a 0.45% gain, marking its fifth week in a row in the green. Foreign inflows continued shoring up the benchmark, though some investors remained cautious about what the next macro developments could bring. InfoMoney

Bradesco’s recurring net income jumped 20.6% year-over-year in the fourth quarter to 6.5 billion reais, according to a regulatory filing. That pushed full-year 2025 recurring net income to 24.7 billion reais. Return on average equity landed at 15.2%. The bank’s expanded loan portfolio wrapped up 2025 at 1.089 trillion reais, reflecting an 11% increase. For 2026, Bradesco is projecting loan growth between 8.5% and 10.5%, and expects net interest income net of provisions to fall in the 42-48 billion reais range. Fee income and insurance are seen growing at a slower pace, while operating expenses are set to rise 6% to 8%.

During the earnings call, chief executive Marcelo Noronha emphasized a patient approach to the overhaul, arguing that ongoing tech investment was essential. “Technology will require growing, constant investing over time,” he said, casting the spending as a necessary step toward a solution—not a sidetrack. Investing.com

XP Investimentos analysts described the quarter as solid and mostly as expected, but pointed out the 2026 guidance still looks cautious, with transformation expenses likely to weigh on costs in the short term. Bradesco’s return on average equity lags behind Itaú Unibanco’s 24.4% and Santander Brasil’s 17.6% for the same stretch—XP highlighted the gap, since Monday updates often bring that sort of comparison front and center. InfoMoney

Bradesco’s American depositary receipts (BBD) slipped 0.5% to $3.98 on Friday, wrapping up a session that saw prices range from $3.845 to $3.99. ADRs give U.S. investors access to foreign stocks via U.S. exchanges. Investing.com

Rates just won’t quit. Fresh talk out of Brasilia this week put the central bank’s rate-setting board back in focus, with speculation swirling over a possible new appointee. Some investors bristled, worried this could open the door to a more politically slanted approach. Economic policy chief Guilherme Mello didn’t soothe nerves, saying debt “depends on monetary policy decisions”—a line that shoved attention straight back onto the interest-rate curve. Reuters

Traders will get two clear signals next week. Brazil’s January IPCA inflation figures hit on Feb. 10, with Banco do Brasil set to release Q4 results a day later, on Feb. 11. Both data points have the potential to shake up rate bets and bank stocks. Investing.com

Stock Market Today

  • Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
    March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).
Stellantis stock slides 24% after €22 billion EV reset kills 2026 dividend — what to watch next
Previous Story

Stellantis stock slides 24% after €22 billion EV reset kills 2026 dividend — what to watch next

Snap stock price bounces to $5.22 after upgrades — what traders watch next week
Next Story

Snap stock price bounces to $5.22 after upgrades — what traders watch next week

Go toTop